Diffuse Large B-Cell Lymphoma
Conditions
Interventions
This is a controlled, randomized, and unblinded clinical study involving patients with relapsed or refractory aggressive Non-Hodgkin Lymphomas, assessing the integration of early palliative care (with
Sponsors
Oncoclínicas Rio de Janeiro S.A
Oncoclínicas Rio de Janeiro S.A
Grupo Oncoclínicas
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diffuse Large B-Cell Lymphoma (DLBCL); Primary Central Nervous System Lymphoma (PCNSL); HTLV-associated Lymphoma, Burkitt Lymphoma; Mantle Cell Lymphoma (MCL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); Peripheral T-Cell Lymphoma (PTCL); transformed indolent Non-Hodgkin Lymphoma; both male or female; over 18 years old; followed in outpatient settings; capable of responding to the required information or accompanied by someone able to do so; who sign the informed consent form
Exclusion criteria
Exclusion criteria: Individuals under 18 years of age; patients who refuse to participate; patientse with a histopathological diagnosis of indolent Non-Hodgkin Lymphoma of the following subtypes: Follicular, Cutaneous T-Cell, and Lymphoplasmacytic
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that there will be a change in the FACT-Lym score from baseline to 12 weeks after the integration of palliative care into oncohematological treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate changes in the scores of the Edmonton Symptom Assessment Scale (ESAS) and the Hospital Anxiety and Depression Scale (HADS), as well as the incidence of treatment in the last 30 days of life, the number of emergency admissions, the location and length of hospitalization, the time and place of death, and overall survival | — |
Countries
Brazil
Contacts
Public ContactCecilia Vaz
Oncoclínicas Botafogo
Outcome results
None listed